{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-270953","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2021-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.055877+00:00","generated_at":"2026-06-29T04:08:50.743077+00:00","sec_items":["4.01","5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aadi Bioscience appoints Emma Reeve to Board, changes auditor to BDO after reverse merger","bullets":["Emma Reeve appointed Class III director and Audit Committee Chair, effective Sept 8, 2021.","Reeve brings experience from Constellation Pharmaceuticals (CFO, oversaw $1.7B sale) and board seats at PTC Therapeutics, Editas Medicine.","Auditor changed: Ernst & Young dismissed, BDO engaged as independent auditor following reverse merger with Old Aadi; no disagreements or reportable events.","Company highlights upcoming PDUFA target action date of Nov 26, 2021 for FYARRO (nab-sirolimus) in PEComa."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-270953","json":"https://secwatch.observer/filing/0001193125-21-270953.json","markdown":"https://secwatch.observer/filing/0001193125-21-270953.md","text":"https://secwatch.observer/filing/0001193125-21-270953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521270953/0001193125-21-270953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521270953/d138836d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T04:08:50.743077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c998ce20c4","claim":"Emma Reeve was appointed as Class III Director at Whitehawk Therapeutics, Inc..","evidence_excerpt":"On September 8, 2021, Emma Reeve was appointed a Class III director by the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521270953/0001193125-21-270953-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}